$CURR CURE Pharmaceutical Expands Cannabis Extrac
Post# of 72712
(Total Views: 142)
Posted On: 05/13/2020 11:48:18 AM
$CURR CURE Pharmaceutical [OTCQB:CURR] Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by process” patents for obtaining multiple unique cannabis concentrates using super critical fluid extraction (SCFE). These include cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.
“Adding CBG to our SCFE patent portfolio aligns with the latest research and early clinical evidence supporting its therapeutic benefit,” said Rob Davidson, CEO of CURE Pharmaceutical. “We continue to expand this portfolio to the latest commercial applications for SCFE, providing our patent licensees and their customers expanded IP rights.”
CURE is granting equipment manufacturers, cannabis processing companies and cannabinoid drug developers licenses to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced SCFE technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has retained all rights to applying these methods in oral thin films.
The two patents cover the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. This extraction and fractioning of bioactive cannabinoid molecules allows for the integration of these molecules into dosage forms.
About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S, Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at http://www.curepharma.com.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact:
Paulo Acuna
pacuna@olmsteadwilliams.com
310-824-9000
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by process” patents for obtaining multiple unique cannabis concentrates using super critical fluid extraction (SCFE). These include cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.
“Adding CBG to our SCFE patent portfolio aligns with the latest research and early clinical evidence supporting its therapeutic benefit,” said Rob Davidson, CEO of CURE Pharmaceutical. “We continue to expand this portfolio to the latest commercial applications for SCFE, providing our patent licensees and their customers expanded IP rights.”
CURE is granting equipment manufacturers, cannabis processing companies and cannabinoid drug developers licenses to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced SCFE technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has retained all rights to applying these methods in oral thin films.
The two patents cover the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. This extraction and fractioning of bioactive cannabinoid molecules allows for the integration of these molecules into dosage forms.
About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S, Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at http://www.curepharma.com.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact:
Paulo Acuna
pacuna@olmsteadwilliams.com
310-824-9000
(0)
(0)Scroll down for more posts ▼